Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma

Mario Airoldi, Fulvia Pedani, Sara Marchionatti, Anna Maria Gabriele, Giovanni Succo, Pietro Gabriele, Cesare Bumma

Research output: Contribution to journalArticlepeer-review


Background: Recurrent undifferentiated nasopharyngeal carcinoma is a chemosensitive disease. Few third-line treatments have been reported. Methods: Twelve patients (9 males, 3 females; median age 50 years, range, 20-62) with recurrent undifferentiated nasopharyngeal carcinoma were treated with carboplatin AUC 5.5 + paclitaxel (175 mg/m2, 3-hr infusion) on day 1 every 3 weeks. All patients had been previously treated for recurrent disease with a first-line cisplatin-based chemotherapy and a second-line therapy with low-dose continous infusion 5-fluorouracil. Results: Overall, 54 courses were given (median, 5; range, 2-6). Three patients (25%) obtained a partial response lasting 6, 10 and 26+ months, 1 (8.3%) a minimal response lasting 6 months, and 3 (25%) no change with a median duration of 5 months. The median survival time was 14 months for patients who had a partial or minimal response or no change, and 5 months for nonresponders. Median overall survival was 9.5 months (3-30+). The treatment was well tolerated, and toxicity was manageable. Conclusions: The combination has a good pallitive role as third-line chemotherapy in recurrent undifferentiated nasopharyngeal cancer.

Original languageEnglish
Pages (from-to)273-276
Number of pages4
Issue number4
Publication statusPublished - Jul 2002


  • Carboplatin
  • Chemotherapy
  • Nasopharyngeal cancer
  • Taxol

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma'. Together they form a unique fingerprint.

Cite this